Boston Scientific Corp. (NYSE:BSX)

Total inventories exhibited a general upward trajectory between 2018 and 2022, increasing from US$ 1,166 million to US$ 1,867 million. This represents a total increase of approximately 60% over the five-year period, despite a notable contraction occurring in 2020.

Finished Goods Composition

Finished goods constitute the largest portion of the inventory portfolio. This category grew from US$ 760 million in 2018 to US$ 1,172 million in 2022. A temporary decline was observed in 2020, falling to US$ 893 million, followed by a recovery and subsequent expansion in 2021 and 2022.

Raw Materials Growth

Raw materials demonstrated significant growth, rising from US$ 306 million in 2018 to US$ 548 million in 2022. This category saw a relative increase of nearly 79%, suggesting a strategic accumulation of inputs or an expansion in production capacity to meet future demand.

Work-in-Process Volatility

Work-in-process inventory remained the smallest component of the total. It experienced significant volatility, peaking at US$ 192 million in 2019 before dropping to US$ 109 million in 2020. By the end of 2022, this value stabilized at US$ 147 million.

Annual Variance and Recovery

A synchronized decrease across all inventory categories occurred in 2020, where total inventories dropped from US$ 1,579 million to US$ 1,351 million. This downturn was followed by a sharp rebound in 2021 and 2022, with the total inventory level exceeding pre-2020 peaks by December 31, 2022.